Health Research Coordination, Centro Medico Nacional, Instituto Mexicano del Seguro Social (IMSS), Mexico.
School of Rehabilitation Sciences, Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada.
Exp Gerontol. 2019 Sep;124:110624. doi: 10.1016/j.exger.2019.05.013. Epub 2019 May 29.
Atherosclerosis is a primary risk factor for cardiovascular disease (CVD). Proinflammatory biochemical factors can influence vascular health; monocyte chemoattractant protein-1 (MCP-1) is elevated in patients with CVD while fibroblast growth factor-21 (FGF-21) acts directly on cardiac tissue to reduce infarction damage. However, the relationship between plasma concentrations of MCP-1, FGF-21 and subclinical CVD indices remains equivocal.
To determine the association between MCP-1, FGF-21 and subclinical atherosclerosis [i.e., carotid intima-media thickness (cIMT)] in women without clinical evidence of CVD.
A cross-sectional analysis of 140 women without history of CVD was performed. Anthropometrics were collected, serum concentrations of MCP-1 and FGF-21 were determined by enzyme-linked immunosorbent assay, and cIMT was quantified (B-mode ultrasonography). The correlations between MCP-1, FGF-21 and the presence of clinical and laboratory of subclinical atherosclerosis (i.e., cIMT ≥0.70 mm), comparison intergroup and odd ratio with multiple logistic regression were analyzed.
MCP-1, but not FGF-21 correlated with some obesity indicators. In median comparison among groups, subclinical atherosclerosis showed higher serum concentrations of MCP-1and lower serum concentrations of FGF-21. In postmenopausal women, there were significant differences MCP-1 (p = 0.001), and FGF-21 (p = 0.010). Multiple logistic regression analysis in postmenopausal women with subclinical atherosclerosis, between MCP-1 (p = 0.001) and FGF-21 (p = 0.037) showed association with cIMT, along with age.
MCP-1 and FGF-21 levels are associated with subclinical atherosclerosis disease severity (i.e., cIMT) in postmenopausal women without CVD. Further efforts focused on characterizing the relationship between novel blood-borne markers of early CVD pathology are warranted and should be pursued.
动脉粥样硬化是心血管疾病（CVD）的主要危险因素。促炎生化因子会影响血管健康；单核细胞趋化蛋白-1（MCP-1）在 CVD 患者中升高，而成纤维细胞生长因子-21（FGF-21）则直接作用于心脏组织，减少梗塞损伤。然而，血浆 MCP-1、FGF-21 浓度与亚临床 CVD 指标之间的关系仍存在争议。
确定无 CVD 临床证据的女性中 MCP-1、FGF-21 与亚临床动脉粥样硬化（即颈动脉内膜中层厚度[cIMT]）之间的关系。
对 140 名无 CVD 病史的女性进行横断面分析。收集人体测量学数据，通过酶联免疫吸附试验测定 MCP-1 和 FGF-21 的血清浓度，并通过 B 型超声量化 cIMT。分析 MCP-1、FGF-21 与临床和实验室亚临床动脉粥样硬化（即 cIMT≥0.70mm）之间的相关性，并通过多元逻辑回归进行组间比较和比值比分析。
MCP-1 而不是 FGF-21 与一些肥胖指标相关。在组间中位数比较中，亚临床动脉粥样硬化表现出更高的血清 MCP-1 浓度和更低的血清 FGF-21 浓度。在绝经后妇女中，MCP-1（p=0.001）和 FGF-21（p=0.010）存在显著差异。在绝经后亚临床动脉粥样硬化妇女的多元逻辑回归分析中，MCP-1（p=0.001）和 FGF-21（p=0.037）与 cIMT 相关，同时与年龄相关。
MCP-1 和 FGF-21 水平与无 CVD 的绝经后妇女亚临床动脉粥样硬化疾病严重程度（即 cIMT）相关。进一步努力描述早期 CVD 病理新型血液标志物之间的关系是必要的，应予以推进。
